Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ya it really pisses me off, I hate shorts. In my opinion this could be defined as naked shorting since it is so ridiculously high. I emailed CBIS about it once when they were getting hit really hard and they said they could hire a company that is called a short buster to deal with it but said it shouldn't matter with their rate of progress so they didn't. Anyways thank god for this coming into effect soon http://www.sec.gov/news/press/2010/2010-26.htm. I'm also hoping for a really epic short squeeze soon!
Ya no joke, major squeeze coming imo.
I wonder how bad the shorts are today.
Lol awesome. It just keeps getting better and better as the Beatles would say.
I like the volume! Closing green would be even more awesome.
Thanks for the PM today, grabbed like 70,000 shares. Things are looking awesome!
Haha. I've been polishing my moon shoes.
Overall Average: 96% Buy
http://barchart.com/opinions/stocks/CMSI
This is going to be one epic week. Makes it hard for me to sleep aswell.
CMSI ftw
CMSI ftw
PR May 20, 2010
Cannabis Science Identifies Another Urgent Need for Its Pharmaceutical Products as Suicides and Sudden Deaths Among Vets With Post Traumatic Stress Disorder Linked to a Number of Widely-Prescribed FDA Approved Pharmaceuticals Such as Seroquel and Other Antipsychotics, Antidepressants, Mood Stabilizers, Sleep Inducers, Pain, and Seizure Medications
COLORADO SPRINGS, Colo., May 20, 2010 (GlobeNewswire via COMTEX) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, notes with great sadness that a widely prescribed medication has been linked to both suicides and sudden death among veterans suffering from PTSD. Numerous veterans who have contacted Cannabis Science have confirmed these problems.
According to an article by Martha Rosenberg, originally published on Alternet.org and published in March on NewsBlaze.com, at least 87 military men have died in the past six years while prescribed Seroquel and similar drugs. http://newsblaze.com/story/20100324080950rose.nb/topstory.html
Rosenberg reported, "Death certificates and other records collected by veteran family members suggest more than 100 similar deaths among Iraq and Afghanistan combat vets and other military personnel, many on PTSD cocktails with Seroquel and other antipsychotics, antidepressants, mood stabilizers, sleep inducers and pain and seizure medications."
Although not approved for PTSD, Pentagon purchases of Seroquel nearly doubled between 2003 and 2007. Elspeth Ritchie, medical director of the Army's Strategic Communications Office, told the Denver Post the drug is "increasingly utilized as an adjunct for PTSD." Seroquel had almost $5 billion in sales last year.
Dr. Robert Melamede, PhD., Cannabis Science President and CEO, noted, "Of course, after more than 5,000 years of use, cannabis has not been shown to have caused a single death, and it is now widely -- but illegally -- used by veterans and others with PTSD as we have reported. It is shameful that those who deserve the best treatment available are being denied access to cannabis while they are given a cocktail of powerful drugs that seems to be killing them."
On March 31, Cannabis Science issued a press release calling for public support for vets after the New York Times reported that VA Doctors are prohibited from "recommending" cannabis for Post Traumatic Stress Disorder (PTSD). Also, Cannabis Science has previously reported that Dr. Mitch Earleywine, PhD., of the State University of New York (Albany) has surveyed over 1,300 veterans and others who find cannabis very helpful with PTSD.
Cannabis Science Chief Financial Officer Richard C. Cowan stated, "Due to the magnitude and nature of the problem, it is clear why we are focusing our initial FDA pharmaceutical products on PTSD. The fact that Seroquel had $5 billion in sales last year is a strong indication of the potential market for Cannabis Science products."
One of Seroquel first backers, Richard Borison, former chief of psychiatry at the Charlie Norwood VA Medical Center, lost his medical license, was fined $4.26 million and went to prison for a swindle involving Seroquel's original clinical studies.
And last year, Seroquel manufacturer AstraZeneca agreed to pay $520 million to settle suits pertaining to clinical trials and illegal Seroquel marketing.
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Cannabis Science, Inc.
By Staff
CONTACT: CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
Investor Relations
Mark J. Freedman
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
-0-
INDUSTRY KEYWORD: Business Services
SUBJECT CODE: MEDICAL
Company Announcement
"As of May 6, 2010, the Company has changed its authorized amount of common shares from 250,000,000 to 500,000,000 shares of common stock authorized" -8K May 10, 2010
The A/S now being 500 million has nothing to do with the split first of all. Also since a split does not increase or decrease the market capitalization, it is not dilution. It is just a split...and in this case it is actually a dividend. Here's a simple website that might aid you in discerning the difference. http://www.investopedia.com. Lol gl.
lol? Dilution and stock split are totally different terms, what you are saying makes no sense. That is like saying an apple is an orange.
Haha that is probably a good idea. If we can just close green today, we will be looking great for tomorrow and next week.
Seems you are implying this is some sort of Pump and Dump. For that I say you should do some more DD, maybe go visit them if you would like. Most P&D's also like to hide the insider selling and don't file something days after the fact. This company is about as transparent as they come. GLTA
Haha you can see the shorts doing all they can to keep this baby down. Next week this will fly though imo!
I don't know what term of an investor you are (long or short) but even those inside sales you are referring to are helpful for the long term of CMSI.
Everyone knows its all blue skies from here imo. GLTA
You should sticky this PR from May 19th, 2010.
Cannabis Science Comments on Recent USA TODAY Article That The Obama Administration Refocuses Its Unsuccessful War On Drugs to a Public Health Fight and Speaks About the Growing Recognition of Marijuana for Medical Purposes
COLORADO SPRINGS, Colo., May 19, 2010 (GlobeNewswire via COMTEX) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce that as reported in a recent article in USA TODAY the use of marijuana for Medical purposes is becoming more accepted by government officials and by the overwhelming majority of the people. According to the article, "a consensus is growing across the country that at least marijuana will someday be regulated and sold like tobacco and alcohol."
The Obama administration has recently announced the reassessment of its War On Drugs to be refocused as a Public Health Fight after 40 years, $1 Trillion dollars and thousands of lives lost. This has even brought out the support of various law enforcement personnel, including the Medford, Mass.-based Law Enforcement Against Prohibition, a group of over 13,000 police, judges, prison wardens, prosecutors and others who want to legalize and regulate all drugs. The Obama administration said it will not target marijuana dispensaries if they are compliant with state regulations.
Dr. Robert Melamede, PhD., Cannabis Science President and CEO, commented, "Cannabis Science is very pleased to see the growing support for the medical use of marijuana and looks forward to the upcoming Fall vote for South Dakota residents on whether to allow marijuana for medical practice use and the vote in November for by California voters that will decide whether to legalize marijuana. I encourage everyone in these States to vote so we can continue the increasing recognition of the benefits of medical marijuana. We are building a patient oriented company that supports the rights of the individual and opposes the use of state violence against sick and dying Americans, especially our veterans who have sacrificed so much for the freedom that they are now being denied."
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward-Looking Statements: This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Cannabis Science, Inc.
By Staff
CONTACT: CONTACT: Cannabis Science, Inc.
Dr. Robert J. Melamede, PhD., President & CEO
1-888-889-0888
Investor Relations
Mark J. Freedman
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
-0-
INDUSTRY KEYWORD: Business Services
SUBJECT CODE: BIOTECHNOLOGY
HEALTH
MEDICAL
PHARMACEUTICALS
Company Announcement
Yep yep. Getting in before the split could mean a nice gain, especially at these prices.
Too many MM games over the past couple days. They must be desperate for shares. Hopefully we can catch them with their pants down.
MJNA did one last year, go check out their historical prices. If I am not mistaken it ran to something like $1.50 pre split and then from .15 to .5 post split.
Me too. A green close today could start giving us the momentum we need.
$1.50
Haha its funny how small the float was before last Wednesday's run, can't wait to see what the new no float does to next Wednesday's run...
Things seem to be warming up over here...
Definitely...they can cover into our next run though :)
I don't know that we will break .68 but I think we can definitely finish somewhere in the .60's. Loading up today in the .50's was awesome imo.
.45 will have been our low until after the F/S imo. Seeing how quickly its reacted since then shows nice support around these levels. We may do one more little drop to low .50's but I'm thinking we move back to .70's by EOW.
Hope you bought some at around .5. We be bouncin!
Nice buy volume coming in!! Lets knock out those .5's today.
I honestly believe that next week could be even greater than last week. There are definitely more eyes over here than ever and as much of a scramble there was last week to get shares, it will be even harder next week. Not to mention CMSI is in a very rapid growth stage and I wouldn't count out a nice little PR soon.
Indeed! Looks like we are going to be steadily going up from this point over the next couple weeks. Pretty exciting! That twitter update was nice too! The revenues will start pouring in after we OWN some dispensaries and aren't just doing the processing. CMSI = McDonalds for weed.
Ya we may have bottomed out, most of the float is already held by longs. I would say the sell off is more profit taking and some panicking rather than the 10Q.
We will be seeing dollar land again by end of next week. Its like people are just giving money away today! Weeeeeeee.
Snag some cheap ones while you still can imo!